270 related articles for article (PubMed ID: 32681436)
41. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
42. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
[TBL] [Abstract][Full Text] [Related]
43. The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.
Tenggara JB; Rachman A; Prihartono J; Rachmadi L; Panigoro SS; Heriyanto DS; Sutandyo N; Nasution IR; Rahadiati FB; Steven R; Betsy R; Juanputra S; Sudoyo AW
BMC Res Notes; 2024 Feb; 17(1):44. PubMed ID: 38308298
[TBL] [Abstract][Full Text] [Related]
44. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Jeong JY; Park TI; Ahn D
Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract][Full Text] [Related]
47. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
48. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
49. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
Vlajnic T; Baur F; Soysal SD; Weber WP; Piscuoglio S; Muenst S
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):726-730. PubMed ID: 36165931
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
51. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
52. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
[TBL] [Abstract][Full Text] [Related]
53. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
54. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
[TBL] [Abstract][Full Text] [Related]
55. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
56. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
57. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
58. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
[TBL] [Abstract][Full Text] [Related]
59. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]